Additionally, Daiichi Sankyo has partnered with MSD in a $22bn deal to advance ADCs targeting HER3, B7-H3, and CDH6. Each therapy in this pipeline utilises Daiichi Sankyo’s DXd technology.

Japan's Daiichi Sankyo has agreed a deal to buy Ambit Biosciences of the US for up to $410 million, bringing a new leukaemia candidate into its pipeline. The $15-per-share cash deal - which could ...

Over five years on, Daiichi Sankyo has an established presence in the UK, a growing oncology pipeline with treatments in clinical development across multiple types of cancer, and a second ...

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

Malaysia's IHH Healthcare may be entitled to damages of up to $1.25 billion from Japan's Daiichi Sankyo for blocking its bid for control of Indian hospital operator Fortis , according to a report ...

Daiichi Sankyo promoted Hiroyuki Okuzawa to CEO, and he will take over from Sunao Manabe on April 1. Okuzawa is currently ...

Daiichi Sankyo (OTCPK:DSKYF) (OTCPK:DSNKY) announced Friday that an expert panel of the EU drug regulator, the European Medicines Agency (EMA), endorsed its antibody-drug conjugate Dato-DXd ...

Daiichi Sankyo’s Q3 FY2024 results reflect strong performance in oncology, driven by ENHERTU’s market leadership and robust sales growth across regions. Despite regulatory delays for Datroway ...

Ken Keller, Global Head of Oncology Business, and President and CEO, Daiichi Sankyo, Inc., said ... marks the fourth medicine from our oncology pipeline to receive approval in the US." ...

TOKYO, January 31, 2025--(BUSINESS WIRE)--Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive Officer (CEO ...